drugset / Trial / NCT01264367

A Study to Evaluate the Efficacy and Safety of Clevudine and Peg-interferon in Sequence Compared With Clevudine Alone in the Patients With HBeAg(+) Chronic Hepatitis B or Clevudine and Peg-interferon Sequential Treatment in Patients With Chronic Hepatitis B Who Have HBeAg(+)

NCT01264367

Phase 4 Completed 60 enrolled Bukwang Pharmaceutical
RandomizedParallel-groupOpen-labelTreatment

Summary

A study to evaluate the efficacy and safety of clevudine and peg-interferon in sequence compared with clevudine alone in the patients with HBeAg(+) chronic Hepatitis B or clevudine and peg-interferon sequential treatment in patients with chronic Hepatitis B who have HBeAg(+)

Timeline

Start
2008-12
Primary completion
2013-08
Completion
2014-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Clevudine Small molecule 30 mg
Comparator Peginterferon alfa-2a Protein / enzyme biologic 180 ug